Non-functional cookies used by us for site improvements can be declined. Cookie Policy Accept Cookies Video Hero Poster Enhancing critical medicines Learn More ADVANZ PHARMA is a specialty pharmaceutical company with a strategic focus on complex medicines in Europe that is committed to improving the lives of patients by enhancing the critical medicines they depend on. We could not do this without the resilience and entrepreneurial spirit of our people, the successful collaboration with our partners, and intrinsic guidance of our values to help us achieve our purpose while becoming a truly dynamic, progressive company in the process. Our Purpose Our portfolio — At ADVANZ PHARMA, our European hospital portfolio of complex medicines focuses on Anti-infectives, Endocrinology and Critical Care medicines. This is bolstered by an established brands business unit of more than 180 molecules sold into 100 countries across a wide range of therapy areas such as CVD, pain management, ophthalmology, urology, and central nervous system disorders. Careers & Culture — The success of any company is driven by its people. We are no different. Our teams are made up of people who come from all walks of life and backgrounds, and thrive in an environment where diversity is celebrated but where we are all united by the same passion, to help improve the lives of patients by enhancing the critical medicines they depend on. Responsibility — ADVANZ PHARMA is committed to improving the lives of patients by enhancing the critical medicines they depend on. Partnerships are a fundamental part of this, and is vital to creating new, lasting relationships, where we can continue to invest significantly in products to help broaden patient access and health outcomes. Our Partnerships — ADVANZ PHARMA is committed to improving the lives of patients by enhancing the critical medicines they depend on. Partnerships are a fundamental part of this, and is vital to creating new, lasting relationships, where we can continue to invest significantly in products to help broaden patient access and health outcomes. Investors — Our goal is clear – to become the go to partner when commercialising complex medicines in European hospitals We will do this by investing significantly in our portfolio through a combination of pipeline development and acquisition. Contact Us — Corporate Headquarters Direct: +44 (0) 208 588 9100 Compliance Hotline: +1 855 562 5982 www.advanzpharma.ethicspoint.com Latest News — Previous Press Releases — 18 Nov 2021 ADVANZ PHARMA makes key changes to senior leadership to further accelerate next phase of growth Press Releases — 11 Nov 2021 ADVANZ PHARMA announces launch of MYRELEZ® in Norway, the first generic lanreotide for the treatment of acromegaly and gastroenteropancreatic neuroendocrine tumours (GEP-NETs) ADVANZ PHARMA announces launch of MYTOLAC® in Germany, the first generic lanreotide for the treatment of acromegaly and gastroenteropancreatic neuroendocrine tumours (GEP-NETs) ADVANZ PHARMA enters into agreement to acquire the rights to Eisai’s Zonegran® in the EU, Middle East, Russia and Australia Next About Responsibility Partnering News Careers Contact Ethics & Transparency Modern Slavery Statement Product Risk Materials Terms & Conditions Privacy Policy Recruitment Scams Follow us on LinkedIn Copyright 2021 ADVANZ PHARMA®. All Rights Reserved